Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be ...

Cadrenal Therapeutics: Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused. Howev ...
MedPage Today on MSN

Anticoagulant Reversal Drug Pulled From U.S. Market

In May 2018, andexanet was granted accelerated approval as the sole antidote on the market for the DOACs rivaroxaban (Xarelto ...
MedPage Today on MSN

The Latest on Preventing VTE in Multiple Myeloma

Incidence of venous thromboembolism remains 'substantial' despite expert guidelines and newer risk prediction scores ...